Peripartum cardiomyopathy (PPCM) is a cause of pregnancy-associated heart failure. It
typically develops during the last month of, and up to 6 months after, pregnancy in women …

The overall lifetime risk of heart failure (HF) is similar between men and women, however,
there are marked sex differences in the landscape of this condition that are both important …

The reductions in mortality and morbidity being achieved among cancer patients with current
therapies represent a major achievement. However, given their mechanisms of action, many …

Postpartum cardiomyopathy (PPCM) is a disease of unknown etiology and exposes women
to high risk of mortality after delivery. Here, we show that female mice with a cardiomyocyte …

Background—Patients with an activated renin-angiotensin system (RAS) or genetic
alterations of the RAS are at increased risk of myocardial infarction (MI). Administration of …

Background—Peripartum cardiomyopathy (PPCM) is a potentially life-threatening heart
disease that occurs in previously healthy women. We identified prolactin, mainly its 16-kDa …

Peripartum cardiomyopathy (PPCM) is an often fatal disease that affects pregnant women
who are near delivery, and it occurs more frequently in women with pre-eclampsia and/or …

Background—Endothelial nitric oxide (eNO) bioavailability is severely reduced after
myocardial infarction (MI) and in heart failure. Statins enhance eNO availability by both …

Peripartum cardiomyopathy (PPCM) is a life-threatening pregnancy-associated
cardiomyopathy in previously healthy women. Although PPCM is driven in part by the 16 …

Dosage compensation is a regulatory process that insures that males and females have
equal amounts of X‐chromosome gene products. In Drosophila, this is achieved by a 2‐fold …